Applied DNA Sciences, Inc. (NASDAQ:APDN) has a beta value of 0.99 and has seen 4,111,526 shares traded in the last trading session. The company, currently valued at $42.06 Million, closed the last trade at $8.99 per share which meant it gained $0.96 on the day or 11.96% during that session. The APDN stock price is -119.02% off its 52-week high price of $19.69 and 71.97% above the 52-week low of $2.52. If we look at the company’s 10-day average daily trading volume, we find that it stood at 483.51 Million shares traded. The 3-month trading volume is 1.72 Million shares.
The consensus among analysts is that Applied DNA Sciences, Inc. (APDN) is a Buy stock at the moment, with a recommendation rating of 2. None of the analysts rate the stock as a Sell, while none rate it as Overweight. None out of 2 have rated it as a Hold, with 2 advising it as a Buy. None have rated the stock as Underweight. The expected earnings per share for the stock is -$0.67.
Applied DNA Sciences, Inc. (NASDAQ:APDN) trade information
Sporting 11.96% in the green today, the stock has traded in the green over the last five days, with the highest price hit on Thursday, Jul 16 when the APDN stock price touched $9.83-8 or saw a rise of 8.55%. Year-to-date, Applied DNA Sciences, Inc. shares have moved 114.56%, while the 5-day performance has seen it change 10.51%. Over the past 30 days, the shares of Applied DNA Sciences, Inc. (NASDAQ:APDN) have changed 19.07%. Short interest in the company has seen 381.59 Million shares shorted with days to cover at 221.85.
Wall Street analysts have a consensus price target for the stock at $19.5, which means that the shares’ value could jump 116.91% from current levels. The projected low price target is $18 while the price target rests at a high of $21. In that case, then, we find that the current price level is +133.59% off the targeted high while a plunge would see the stock lose 100.22% from current levels.
Applied DNA Sciences, Inc. (APDN) estimates and forecasts
Figures show that Applied DNA Sciences, Inc. shares have underperformed across the wider relevant industry. The company’s shares have gained +92.11% over the past 6 months, with this year growth rate of -77.06%, compared to -6.8% for the industry. Other than that, the company has, however, increased its growth outlook for the 2020 fiscal year revenue. Growth estimates for the current quarter are 58.1% and 89.7% for the next quarter. Revenue growth from the last financial year stood is estimated to be -11.1%.
2 analysts offering their estimates for the company have set an average revenue estimate of $800Million for the current quarter. 2 have an estimated revenue figure of $2.8 Million for the next quarter concluding in September 01, 2020. Year-ago sales stood $2.05 Million and $1.67 Million respectively for this quarter and the next, and analysts expect sales will grow by -61% for the current quarter and 67.4% for the next.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was +24.2% over the past 5 years. Earnings growth for 2020 is a modest +38.9%.